CLINICAL_TRIALS
trial_result
· 2026-03-10
Clinical Trial Update: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine [Phase 3]
Summary
A Phase 3 study of lasmiditan (LY573144) for acute treatment of migraine in children aged 6 to 17 was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Eli Lilly and Company | Conditions: Migraine | Phase 3 | Status: TERMINATED